Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 study of VX-152, a next-generation corrector alone and in combination with VX-661/ivacaftor in healthy volunteers

Next Previous
Search
Trial Profile

Phase 1 study of VX-152, a next-generation corrector alone and in combination with VX-661/ivacaftor in healthy volunteers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Apr 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VX 152 (Primary) ; Ivacaftor/tezacaftor
  • Indications Cystic fibrosis
  • Focus Adverse reactions

Most Recent Events

  • 27 Apr 2016 Status changed from not yet recruiting to recruiting, as reported by Vertex media release.
  • 30 Oct 2015 New trial record
  • 09 Oct 2015 According to a Vertex Pharmaceutical media release, this trial will begin in November 2015.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top